Your browser doesn't support javascript.
loading
Dengue vaccines: progress and challenges.
Coller, Beth-Ann G; Clements, David E.
Afiliação
  • Coller BA; Vaccines Research, WP17-2131, Merck and Company, 770 Sumneytown Pike, P.O. Box 4, West Point, PA 19486, United States. beth-ann.coller@merck.com
Curr Opin Immunol ; 23(3): 391-8, 2011 Jun.
Article em En | MEDLINE | ID: mdl-21514129
ABSTRACT
With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine disease severity remain, but with prospective studies ongoing in various dengue endemic areas and the initiation of dengue vaccine efficacy trials, immune responses are being evaluated in the context of protection and severe disease and these studies are highly likely to provide additional insights.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Dengue / Vacinas contra Dengue Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Curr Opin Immunol Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Dengue / Vacinas contra Dengue Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Curr Opin Immunol Ano de publicação: 2011 Tipo de documento: Article